Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II diagnostic performance study of [68Ga]-NeoBOMB1 in GRPR-overexpressing malignancies
2017-003432-37Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Nov 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68 DOTA-NeoBOMB1 in breast cancer and cancer, sponsored by Advanced Accelerator Applications. Primary endpoint: Number and location of tumour lesions detected by [68Ga]-NeoBOMB1. Started Nov 2017; status: terminated.
02
Drugs
gallium Ga 68 DOTA-NeoBOMB1
03
Conditions
breast cancercancer
Beyond the preview
Go deeper on 2017-003432-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003432-37.